Spots Global Cancer Trial Database for Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Official Title: Local Treatment in Addition to Endocrine Therapy in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR): a Multicentre, Single -Arm, Phase 2 Trial

Study ID: NCT03750396

Conditions

Breast Cancer

Recurrent Breast Cancer

Stereotactic Body Radiotherapy

Estrogen Receptor Positive Tumor

Her2-negative Tumor

Surgery

Interventions

Surgical resection

Stereotactic body radiotherapy

Radiofrequency ablation

Study Description

Brief Summary: Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.

Detailed Description: Local treatment included surgical resection, stereotactic body radiotherapy, palliative radiotherapy, and radiofrequency ablation. Stereotactic body radiotherapy is preferred as a radiation modality. Endocrine therapies with/without target therapy including CDK4/6 inhibitors or mTOR inhibitors are the mainstay of 1st line treatment for ER-positive/HER2-negative metastatic breast cancer.